biote Corp.

Equities

BTMD

US0906831039

Professional Information Services

Market Closed - Nasdaq Other stock markets 16:00:00 2024-07-15 EDT			5-day change	1st Jan Change
8.21 ^USD	+1.36%		+11.10%	+66.19%

07-03	Biote Corp. Announces Termination of Mary Puncochar as Head of Strategic Sales & Business Analytics	CI
07-01	Biote Corp.(NasdaqGM:BTMD) dropped from Russell 2000 Value-Defensive Index	CI

Biote Corp. Announces Termination of Mary Puncochar as Head of Strategic Sales & Business Analytics

July 03, 2024 at 04:06 pm

biote Corp. announced that Mary Puncochar, who has served as the company?s Head of Strategic Sales & Business Analytics since March 2024 and, prior to that, served as Chief Commercial Officer from May 2023 to March 2024, was terminated other than for cause from all employment and officer positions with the company.

Latest news about biote Corp.

Biote Corp. Announces Termination of Mary Puncochar as Head of Strategic Sales & Business Analytics	07-03	CI
Biote Corp.(NasdaqGM:BTMD) dropped from Russell 2000 Value-Defensive Index	06-30	CI
Biote Corp.(NasdaqGM:BTMD) dropped from Russell 2000 Growth-Defensive Index	06-30	CI
Biote Corp.(NasdaqGM:BTMD) dropped from Russell 2000 Defensive Index	06-30	CI
Biote Reaches $60 Million Settlement to Repurchase Shares From Stockholder	06-20	MT
Biote Corp. announces an Equity Buyback for 8,300,000 shares, for $60 million.	06-20	CI
Biote Corp. authorizes a Buyback Plan.	06-19	CI
Biote Shares Fall After Report by Short-Seller J Capital	05-20	MT
Biote Corp. acquired Certain assets of BioSana ID LLC for $0.8 million.	05-09	CI
Earnings Flash (BTMD) BIOTE Reports Q1 Revenue $46.8M, vs. Street Est of $45.7M	05-07	MT
Transcript : Biote Corp., Q1 2024 Earnings Call, May 07, 2024	05-07
Biote Corp. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-07	CI
Biote Corp. Reaffirms Earnings Guidance for the Year 2024	05-07	CI
B. Riley Ups Price Target on Biote to $10 From $9, Maintains Buy Rating	04-05	MT
CORRECTION : --B. Riley Lowers Bitcoin Depot's Price Target to $4 From $6, Maintains Buy Rating	04-03	MT
B. Riley Lowers biote's PT to $4 From $6 After Lower-Than-Expected Q4 2023 Results, Says California Regulations Hit Sales Outlook; Maintains Buy Rating	03-26	MT
Biote Corp. completed the acquisition of Asteria Health.	03-13	CI
Roth MKM Adjusts Price Target on Biote to $9 From $8, Maintains Buy Rating	03-13	MT
Transcript : Biote Corp., Q4 2023 Earnings Call, Mar 12, 2024	03-12
Biote Corp. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-12	CI
Biote Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	03-12	CI
Earnings Flash (BTMD) BIOTE Reports Q4 Revenue $45.7M, vs. Street Est of $45.7M	03-12	MT
Biote Corp. Provides Revenue Guidance for 2024	03-12	CI
B. Riley Securities Starts biote With Buy Rating, $9 Price Target	02-20	MT
Jefferies Starts Biote With Buy Rating, $6.55 Price Target	02-01	MT

Chart biote Corp.

Duration

Period

More charts

Company Profile

biote Corp. operates a practice-building business within the hormone optimization space. The Company provides the necessary components to enable Biote-certified practitioners to establish, build and implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The Biote Method is a comprehensive, end-to-end practice building platform that provides Biote-certified practitioners with the components specifically developed for practitioners in the hormone optimization space: Biote Method education, training and certification, practice management software, inventory management software, and information regarding available hormone replacement therapy (HRT) products, as well as digital and point-of-care marketing support. It also sells a complementary Biote-branded line of dietary supplements. The Biote Methodâs proprietary clinical decision support (CDS) software assists physicians in establishing individualized dosing for patients.

Sector

Professional Information Services

Calendar

2024-08-06 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company